bluuebunny/crossref_metadata_2025_split huggingface dataset:
A Cross-Laboratory Investigation of Timing Endophenotypes in Mouse Behavior
Authors: Maggi Silvia , Garbugino Luciana , Heise Ines , Nieus Thierry , Balcı Fuat , Wells Sara , Tocchini-Valentini Glauco P. , Mandillo Silvia , Nolan Patrick M. , Tucci Valter 
Published: November 2013

Phenotyping behavioral and cognitive processes is a critical practice in mouse research and reliable phenotypic assessment is an essential component of building well-defined links between genes and behavioral/cognitive functions.
The success of behavioral screens in neurobehavioral mouse genetics depends on the identification of reliable, reproducible, and high-throughput behavioral/cognitive measures from individual animals irrespective of the differences in opinions regarding how to tackle phenotyping in different behavioral domains. Furthermore, reliable behavioral assays must be resistant to inevitable environmental differences across laboratories since protocols can be replicated but not all the environmental conditions.
Here we present a cross-laboratory study of interval timing behaviors in mice. Two classically used mouse inbred substrains, C57BL/6J and C57BL/6N, were studied over several days in home-cages containing automated testing apparatus. Remarkably, all timing measures in mouse performance showed a robust reproducibility across centers and even small differences between the two substrains were comparable across laboratories. Moreover, we have observed a consistent increase in error rate during the light phase of the light–dark cycle, which suggests that mouse performance during this phase is compromised by a possible sleep inertia-like effect. Overall, our study demonstrates that analysis of mouse timing behavior can lead to robust and reliable endophenotypes in mouse behavioral genetic studies.
Treatment of Aortoiliac Aneurysms With the Iliac Bifurcated Device for Preservation of Internal Iliac Artery Flow
Authors: Chowdhury Mohammed M. , Schiro Andrew , Farquharson Finn , Smyth J. V. , Serracino-Inglott Ferdinand , Murray David 
Published: November 2013

Introduction: The iliac bifurcated device (IBD) is an innovative endovascular device for aortoiliac aneurysm repair. The objective of this study is to provide further evidence on the efficacy and safety of the device. Study Design: Case series study with retrospective analysis of prospectively collected nonrandomized data. Methods: Between 2007 and 2010, all consecutive IBD placements were analyzed. The main outcomes included (1) technical failure; (2) morbidity and mortality; and (3) late outcomes. Prospective follow-up was performed by interval computed tomography scanning. Results: In all, 27 consecutive patients had elective placement of 28 IBDs. Mean operating time was 251.1 ± 65.4 minutes, mean fluoroscopy time was 63.9 ± 27.2 minutes, and mean contrast volume used was 186.2 ± 106.7 mL. Periprocedural type I endoleak occurred in 2 patients. No aneurysm-related adverse events were recorded. Conclusion: We demonstrate that IBDs can be used in patients with aortoiliac aneurysms and are associated with satisfactory medium-term results as expressed by high patency and low reintervention rates.
Functional equations and inequalities in matrix paranormed spaces
Authors: Park Choonkil , Lee Jung Rye , Shin Dong Yun 
Published: November 2013

Abstract
In this paper, we prove the Hyers-Ulam stability of the Cauchy additive functional inequality, the Cauchy additive functional equation and the quadratic functional equation in matrix paranormed spaces.

MSC:47L25, 39B82, 39B72, 46L07, 39B52, 39B62.
Metachronous, colitis-associated rectal cancer that developed after sporadic adenocarcinoma in an adenoma in a patient with longstanding Crohn’s disease: a case report
Authors: Takeyama Hiroshi , Mizushima Tsunekazu , Nakajima Kiyokazu , Uemura Mamoru , Haraguchi Naotsugu , Nishimura Junichi , Hata Taishi , Takemasa Ichiro , Yamamoto Hirofumi , Doki Yuichiro , Mori Masaki 
Published: November 2013

Abstract

Background
Colorectal cancer associated with Crohn’s disease (CD) is increasing in proportion to the number of patients with CD in Japan. There are two subtypes of colorectal cancer with CD: sporadic cancer and colitis-associated cancer. Early diagnosis of colitis-associated cancer is sometimes difficult; when colorectal cancer is found in patients with CD, both colitis-associated cancer and sporadic cancer should be kept in mind. Here, we describe a case of metachronous, colitis-associated rectal cancer that developed after the complete resection of an adenoma that became a sporadic adenocarcinoma in a patient with longstanding CD. To the best of our knowledge, this is the first report of colitis-associated cancer in a patient with CD after removal of a sporadic cancer.

Case presentation
We describe a 51-year old man with CD who had difficulty in defecation. A rectal polyp was detected and a transanal resection of the polyp was performed. A histopathological examination showed an adenoma with sporadic adenocarcinoma. After three years, a follow-up colonoscopy revealed a reddish, elevated lesion in the patient’s rectum. A colonoscopic biopsy showed a signet ring cell carcinoma. We performed an abdominoperineal resection of the rectum and a bilateral pelvic lymph node dissection. A histopathological examination revealed a mucinous adenocarcinoma with signet ring cell carcinoma and lymph node metastasis. The patient received adjuvant chemotherapy with oral uracil 224 mg combined with tegafur 100 mg plus leucovorin. No signs of recurrence were noted at a follow-up 18 months after the third surgery and 60 months after the second surgery.
Cardiogenic shock accompanied by dynamic left ventricular outflow tract obstruction and myocardial bridging after transient complete atrioventricular block mimicking ST-elevation myocardial infarction: a case report
Authors: Kang Seonghui , An Sanghee , Yu Hyung Min , Kim Jiwan , Kim Sung Hea , Kim Hyun-Joong , Chung Sang Man 
Published: November 2013

Abstract

Background
Dynamic left ventricular outflow tract obstruction with or without mitral regurgitation is typically observed in hypertrophic cardiomyopathy, but is also occasionally seen without left ventricular hypertrophy. In this report, we present a case of cardiogenic shock that mimics ST-elevation myocardial infarction, due to dynamic left ventricular outflow tract obstruction with transient mitral regurgitation and myocardial bridging after transient complete atrioventricular block.

Case presentation
A 65-year-old man with hypertension presented himself at the emergency department with syncope after chest pain. His initial electrocardiography showed inferior ST elevation with profound precordial ST depression and transient complete atrioventricular block. Due to sustained hypotension, an intra-aortic balloon pump was applied. His coronary angiography revealed almost normal right coronary artery and left circumflex artery and only a severe myocardial bridge in the mid-segment of his left anterior descending artery. Instead, severe mitral regurgitation was found without regional wall motion abnormality both in the left ventriculography and the portable echocardiography. However the severe mitral regurgitation completely disappeared in follow up echocardiography the day after. The pressure gradient across the left ventricular outflow tract was measured at 8.95 mmHg during the resting state, and was increased to 38.95 mmHg during the Valsalva state.

Conclusions
The patient presented with a case of cardiogenic shock that mimicked ST-elevation myocardial infarction due to dynamic left ventricular outflow tract obstruction combined with myocardial bridging in the mid-left anterior descending artery.
Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice
Authors: Impellizzeri Daniela , Esposito Emanuela , Di Paola Rosanna , Ahmad Akbar , Campolo Michela , Peli Angelo , Morittu Valeria Maria , Britti Domenico , Cuzzocrea Salvatore 
Published: November 2013

Abstract
Introduction
N-palmitoylethanolamine (PEA) is an endogenous fatty acid amide belonging to the family of the N-acylethanolamines (NAEs). Recently, several studies demonstrated that PEA is an important analgesic, antiinflammatory, and neuroprotective mediator. The aim of this study was to investigate the effect of co-ultramicronized PEA + luteolin formulation on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis (CIA).

Methods
CIA was induced by an intradermally injection of 100 μl of the emulsion (containing 100 μg of bovine type II collagen (CII)) and complete Freund adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Mice subjected to CIA were administered PEA (10 mg/kg 10% ethanol, intraperitoneally (i.p.)) or co-ultramicronized PEA + luteolin (1 mg/kg, i.p.) every 24 hours, starting from day 25 to 35.

Results
Mice developed erosive hind-paw arthritis when immunized with CII in CFA. Macroscopic clinical evidence of CIA first appeared as periarticular erythema and edema in the hindpaws. The incidence of CIA was 100% by day 28 in the CII-challenged mice, and the severity of CIA progressed over a 35-day period with a resorption of bone. The histopathology of CIA included erosion of the cartilage at the joint. Treatment with PEA or PEA + luteolin ameliorated the clinical signs at days 26 to 35 and improved histologic status in the joint and paw. The degree of oxidative and nitrosative damage was significantly reduced in PEA + luteolin-treated mice, as indicated by nitrotyrosine and malondialdehyde (MDA) levels. Plasma levels of the proinflammatory cytokines and chemokines were significantly reduced by PEA + luteolin treatment.

Conclusions
We demonstrated that PEA co-ultramicronized with luteolin exerts an antiinflammatory effect during chronic inflammation and ameliorates CIA.
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
Authors: Hudis Clifford , Swanton Charles , Janjigian Yelena Y , Lee Ray , Sutherland Stephanie , Lehman Robert , Chandarlapaty Sarat , Hamilton Nicola , Gajria Devika , Knowles James , Shah Jigna , Shannon Keith , Tetteh Ernestina , Sullivan Daniel M , Moreno Carolina , Yan Li , Han Hyo Sook 
Published: November 2013

Abstract
Introduction
Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop resistance through downstream signaling via the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This phase 1 trial was conducted to determine the safety and tolerability of the investigational AKT inhibitor MK-2206, to prepare for future studies to determine whether the combination with trastuzumab could inhibit compensatory signaling.

Methods
Patients with HER2+ treatment-refractory breast and gastroesophageal cancer were enrolled. Treatment consisted of standard doses of intravenous trastuzumab and escalating dose levels of oral MK-2206 using either an every-other-day (45 mg and 60 mg QOD) or once-weekly (135 mg and 200 mg QW) schedule.

Results
A total of 34 patients with HER2+ disease were enrolled; 31 received study-drug. The maximum tolerated dose (MTD) for MK-2206 in combination with trastuzumab was 60 mg for the QOD schedule and 135 mg for the QW schedule, although a true MTD was not established due to early termination of the trial. The most common treatment-emergent toxicities included fatigue, hyperglycemia, and dermatologic rash, consistent with prior experience; one death unrelated to treatment was reported. There was one complete response in a patient with metastatic breast cancer, one patient achieved a partial response, and 5 patients had stable disease for at least 4 months, despite progression on multiple prior trastuzumab- and lapatinib-based therapies. Results also indicate that trastuzumab does not affect the pharmacokinetics of MK-2206.

Conclusions
Results suggest the AKT inhibitor MK-2206 can be safely combined with trastuzumab, and is associated with clinical activity, supporting further investigation.

Trial registration
ClinicalTrials.gov; identifier: NCT00963547.
Pro–Surfactant Protein B As a Biomarker for Lung Cancer Prediction
Authors: Sin Don D. , Tammemagi C. Martin , Lam Stephen , Barnett Matt J. , Duan Xiaobo , Tam Anthony , Auman Heidi , Feng Ziding , Goodman Gary E. , Hanash Samir , Taguchi Ayumu 
Published: November 2013

Purpose Preliminary studies have identified pro–surfactant protein B (pro-SFTPB) to be a promising blood biomarker for non–small-cell lung cancer. We conducted a study to determine the independent predictive potential of pro-SFTPB in identifying individuals who are subsequently diagnosed with lung cancer. Patients and Methods Pro-SFTPB levels were measured in 2,485 individuals, who enrolled onto the Pan-Canadian Early Detection of Lung Cancer Study by using plasma sample collected at the baseline visit. Multivariable logistic regression models were used to evaluate the predictive ability of pro-SFTPB in addition to known lung cancer risk factors. Calibration and discrimination were evaluated, the latter by an area under the receiver operating characteristic curve (AUC). External validation was performed with samples collected in the Carotene and Retinol Efficacy Trial (CARET) participants using a case-control study design. Results Adjusted for age, sex, body mass index, personal history of cancer, family history of lung cancer, forced expiratory volume in one second percent predicted, average number of cigarettes smoked per day, and smoking duration, pro-SFTPB (log transformed) had an odds ratio of 2.220 (95% CI, 1.727 to 2.853; P < .001). The AUCs of the full model with and without pro-SFTPB were 0.741 (95% CI, 0.696 to 0.783) and 0.669 (95% CI, 0.620 to 0.717; difference in AUC P < .001). In the CARET Study, the use of pro-SFPTB yielded an AUC of 0.683 (95% CI, 0.604 to 0.761). Conclusion Pro-SFTPB in plasma is an independent predictor of lung cancer and may be a valuable addition to existing lung cancer risk prediction models.
Substitution for lost one-hour means of the geomagnetic elements for the first half of the 20-th century at the Hurbanovo Geomagnetic Observatory by means of neural networks
Authors: Valach Fridrich , Váczyová Magdaléna , Dolinský Peter , Vajkai Melinda 
Published: November 2013

Abstract
The existence of long-acting observatories by itself does not guarantee that their historical magnetograms are available or complete. In the archive of the Hurbanovo Geomagnetic Observatory (acronym HRB; geographical coordinates 47.86 ◦ N, 18.19 ◦ E), records of the geomagnetic field made on photo paper covering the period between the two World Wars were found for which the values of the baselines are unknown. We studied if a feed-forward neural network with one hidden layer can be used to supplement one-hour means of the geomagnetic elements D, H and Z of observatory HRB, using for this purpose the geomagnetic data of observatories Potsdam, Seddin and Niemegk (all of them being referenced to Niemegk). We focused our interest on the first half of the 20-th century. The neural-network model for element D proved to be applicable to substitute for the lost data of the magnetic declination at observatory HRB; however, the usability of the model for both elements H and Z turned out to be limited to a few years close to beginning or end of data gaps. Further we supplemented the time series of annual means of geomagnetic elements D, H and Z at observatory HRB with the model data.
New approach to cancer therapy based on a molecularly defined cancer classification
Authors: Cortés Javier , Calvo Emiliano , Vivancos Ana , Perez‐Garcia Jose , Recio Juan Angel , Seoane Joan 
Published: November 2013

AbstractTranslational and clinical cancer research, as well as clinical trials and treatment of cancer, are essentially structured based on the organ in which tumors originate. However, the recent explosion of knowledge about the molecular characteristics of tumors is opening a new way to tackle cancer. This article proposes a different approach to the classification of cancer with important implications for treatment and for basic, translational, and clinical research. The authors postulate that cancers from diverse organs of origin with similar molecular traits should be managed together. The common molecular features observed in different tumors determine clinical actions in a better way than organ‐based classification. Thus, comparisons between tumors residing in different locations but with shared molecular characteristics will improve the therapeutic approach and the understanding of the biology of cancer. CA Cancer J Clin 2014;64:70–74. © 2013 American Cancer Society.
L’hébergement des données de santé à caractère personnel
Authors: Richard Christophe , Guigue Laurent 
Published: November 2013

Les données de santé à caractère personnel (DSCP) sont généralement considérées comme des données sensibles dont la collecte ou le traitement informatique sont encadrés par plusieurs textes règlementaires et dans de nombreux cas, interdits sans autorisation spéciale. En France, le cadre législatif de tout traitement informatique de données est encadré depuis 1978 par la loi dite Informatique et libertés et celui concernant spécifiquement l’activité d’hébergement de données de santé à caractère personnel est fixé par l’article L. 1111-8 du code de la santé publique inséré par la loi n° 2002-303 du 4 mars 2002, dite loi « Kouchner ». Ces dispositions ont pour objectif d’organiser et de délimiter le dépôt, la conservation et la restitution des données de santé à caractère personnel, dans des conditions de nature à garantir leur confidentialité et leur sécurité. Il en résulte que toute entité qui conserve des données de santé de personnes pour lesquelles elle n’intervient pas dans la prise en charge médicale est soumise à l’obligation d’être hébergeur agréé. Cet agrément est délivré par le ministre de la santé sur la base de recommandations formulées par l’ASIP Santé et la CNIL par un dossier de demande d’agrément et le cas échéant un audit de la CNIL. Parmi ces obligations, le législateur a imposé la présence d’un médecin, dans toute structure agréée pour l’hébergement de données de santé à caractère personnel : le médecin dit de l’hébergeur. L’existence de plus de 53 décisions d’agrément rendues en date du 10 septembre 2013 par le ministre en charge de la santé, induit l’existence d’une trentaine de médecins en charge de l’activité d’hébergement dans les entités agréées. La majorité d’entre eux se sont regroupés au sein d‘une association avec pour objectif d’engager une réflexion collégiale sur les thématiques identifiées par les Membres et d’être force de proposition auprès des acteurs et institutions compétentes.
Increased Risk of Complications Following Total Joint Arthroplasty in Patients With Rheumatoid Arthritis
Authors: Ravi Bheeshma , Croxford Ruth , Hollands Simon , Paterson J. Michael , Bogoch Earl , Kreder Hans , Hawker Gillian A. 
Published: November 2013

ObjectiveMost of the evidence regarding complications following total hip arthroplasty (THA) and total knee arthroplasty (TKA) are based on patients with osteoarthritis (OA); less is known about outcomes in rheumatoid arthritis (RA). Using a validated algorithm for identifying patients with RA, we undertook this study to compare the rates of complications among THA and TKA recipients between those with RA and those without RA.MethodsIn patients who underwent a first primary elective THA or TKA between 2002 and 2009, those with RA were identified using a validated algorithm: a hospitalization with a diagnosis code for RA or 3 physician billing claims with a diagnosis code for RA, with at least 1 claim by a specialist (rheumatologist, orthopedic surgeon, or internist) in a 2‐year period. Recipients with diagnostic codes suggesting an inflammatory arthritis, but not meeting RA criteria, were classified as having inflammatory arthritis. All remaining patients were deemed to have OA. Cox proportional hazards models, censored on death, were used to determine the relationship between the type of arthritis and the occurrence of specific complications, adjusting for potential confounders (age, sex, comorbidity, and provider volume).ResultsWe identified 43,997 eligible THA recipients (3% with RA) and 71,793 eligible TKA recipients (4% with RA). Total joint arthroplasty recipients with RA had higher age and sex–standardized rates of dislocation following THA (2.45%, compared with 1.21% for recipients with OA) and higher age and sex–standardized rates of infection following TKA (1.26%, compared with 0.84% for recipients with OA). Controlling for potential confounders, recipients with RA remained at increased risk of dislocation within 2 years of THA (adjusted hazard ratio [HR] 1.91, P = 0.001) and remained at increased risk of infection within 2 years of TKA (adjusted HR 1.47, P = 0.03) relative to recipients with OA.ConclusionPatients with RA are at higher risk of dislocation following THA and are at higher risk of infection following TKA relative to those with OA. Further research is warranted to elucidate explanations for these findings, including the roles of medication profile, implant choice, postoperative antibiotic protocol, and method of rehabilitation following joint replacement.
Engineering the MEP pathway enhanced ajmalicine biosynthesis
Authors: Chang Kai , Qiu Fei , Chen Min , Zeng Lingjiang , Liu Xiaoqiang , Yang Chunxian , Lan Xiaozhong , Wang Qiang , Liao Zhihua 
Published: November 2013

AbstractThe 2‐C‐methyl‐D‐erythritol‐4‐phosphate (MEP) pathway genes encoding DXR and MECS from Taxus species and STR from Catharanthus roseus were used to genetically modify the ajmalicine biosynthetic pathway in hairy root cultures of C. roseus. As expected, the STR‐overexpressed root cultures showed twofold higher accumulation of ajmalicine than the control. It was important to discover that overexpression of the single DXR or MECS gene from the MEP pathway also remarkably enhanced ajmalicine biosynthesis in transgenic hairy root cultures, and this suggested that engineering the MEP pathway by overexpression of DXR or MECS promoted the metabolic flux into ajmalicine biosynthesis. The transgenic hairy root cultures with co‐overexpression of DXR and STR or MECS and STR had higher levels of ajmalicine than those with overexpression of a single gene alone such as DXR, MECS, and STR. It could be concluded that transgenic hairy root cultures harboring both DXR/MECS and STR possessed an increased flux in the terpenoid indole alkaloid biosynthetic pathway that enhanced ajmalicine yield, which was more efficient than cultures harboring only one of the three genes.